XII IPLS Speaker Information

Thorsten Umland

VP and Head, Business Development & Licensing Consumer Care

Bayer HealthCare

Dr. Thorsten Umland is Head of Business Development and Licensing for the Consumer Care Division at Bayer HealthCare In this role, he is responsible for all licensing activities and mergers and acquisitions for Consumer Care. He is also a member of the Consumer Care Global Management Team.

Prior to assuming this role in 2012, Thorsten served as Vice President, Corporate Development, and Head of Healthcare Strategy at Bayer AG.

Thorsten began his career in 1999 as Laboratory Head for Cardiovascular Research at BASF AG (later Knoll/Abbott) in Ludwigshafen, Germany. In 2001, he joined Schering AG and held positions of increasing management responsibilities in Schering and Berlex Inc., its U.S.-based operation. Between 2002 and 2003, he created a business development function at the company’s California-based research site, and later headed Corporate Business Development for Oncology and Specialized Therapeutics at the Berlex headquarters in New Jersey. In 2007, Thorsten relocated to Leverkusen, Germany, for his subsequent role in Healthcare Strategy at Bayer AG.

Thorsten received a master’s degree in Human Biology from Philipps University in Marburg, Germany, and a doctorate in Molecular Biology from the German Cancer Research Center in Heidelberg, Germany. He is married with three children and is based at one of Consumer Care’s global hubs in Leverkusen.

Claudio Albrecht

Co-Founder and Managing Partner

Albrecht, Prock & Partners

Claudio Albrecht was, until 2013, the CEO and Chairman of the Board of the Actavis Group. Actavis was among the top 5 Generic companies globally with sales in excess of 2 bio €, 13.000 employees and a presence in more than 60 countries worldwide

Claudio started his pharmaceutical career in Austria at Sandoz / Biochemie in 1987. As Head of Marketing and Sales he was in charge of commercial affairs mainly in Emerging Markets like Latin America, FWA, RSA (Rolab) and Middle East. After the formation of Novartis he was appointed Country Manager of its generics business first in the Netherlands, then in Germany and the USA, before leaving to become CEO of the Ratiopharm Group in Germany with international sales in more than 50 countries worldwide and 6000 employees. With Ratiopharm he was one of the first Generic companies to start up a successful Biosimilars development and manufacturing program. He founded Albrecht Prock and Partners AG, a Swiss company focussing on Strategy Consulting and M&A in the Pharmaceutical Industry (www.ca-pp.net ).

Claudio holds a PhD in Law

Joseph Havrilla

Head of Alliance Management

Bayer HealthCare

Joseph Havrilla is Vice-President and Global Head of Alliance Management for Bayer HealthCare, a role he has held since 2011. Prior to taking on this role he was Head of Business Development and Licensing for Bayer’s Medical Care Radiology and Interventional group.

Before moving to Bayer Health Care Joe was Chief Technology and Strategy Officer for MEDRAD, a medical device subsidiary of Bayer Medical Care. His responsibilities included corporate research, innovation, business development, strategic planning and Intellectual Property.

As head of MEDRAD’s product development organization, Joe’s leadership helped the company launch numerous pioneering new products leading to a sustained 15 percent annual growth rate. He personally holds over 20 United States and foreign patents.

Before joining MEDRAD, Joe held technical and engineering management positions at Xerox, Inc., Rockwell International, Inc. and Recognition Equipment Corporation. He received an MBA from Southern Methodist University, Dallas, Texas and a B.S. in Electrical Engineering from Carnegie Mellon University in Pittsburgh, Pa.

Juergen Beck

Head of Business Development & Licensing/Strategic Transactions

Boehringer Ingelheim

Jürgen Beck is currently heading the BD&L/Strategic Transactions team at Boehringer Ingelheim GmbH, Germany. He leads a team of licensing professionals responsible for structuring and leading business transactions of global partnerships including compound in-licensing, asset acquisitions, out-licensing, co-commercialization, technology-based deals and other deal arrangements.

He has almost 10 years working experience in Business Development and Licensing as well as a strong commercial background in marketing and sales with responsibilities in countries such as Germany and India.

Pascal Touchon

Vice President Business Development & Scientific Cooperation

Servier

Pascal Touchon has 29 years’ experience in the pharmaceutical industry in Research, Marketing and Sales, General Management and Business Development. He has extensive international experience in managing commercial operations and as CEO in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada, and South Africa.

As head of Business Development for Servier over the last 5 years, he led the closing of more than 30 partnerships with biotech companies and academic institutes, managed various existing alliances and conducted two private company acquisitions and a public offer. Servier is a private research based pharmaceutical company with sales of 4.2 billion euros worldwide and activities in cardiovascular diseases, type II diabetes, neurology, psychiatry, rheumatology and oncology.

Pascal holds a Doctorate in Veterinary Medicine, a DESS in Management and an MBA from INSEAD.

Greg Benning

Managing Director, Head of Financial Advisory

Back Bay Life Science Advisors

Mr. Benning is Managing Director, Head of Financial Advisory at Back Bay. Mr. Benning is a career middle market investment banker with over 25 years of client advisory and transactional experience. He has managed and executed over 300 M&A, divestiture and financing transactions, with proceeds totaling over $15B.Previously, Mr. Benning was Head of Mergers and Acquisitions for the emerging growth investment bank, Adams Harkness, and a partner-level banker at the regional investment bank, Tucker Anthony. Most recently, he launched the Northeast US middle market M&A practices for Barrington Associates and A.G. Edwards & Sons, both now parts of Wells Fargo Bank. Mr. Benning is an acknowledged expert on M&A transaction markets, deal structures and acquisition finance, and has presented, spoken and written for organizations including ACG Boston, the Angel Capital Association, Babson College, Boston University, Corporate Board Member, Ernst & Young, IBF’s Venture Capital Summit, the Nantucket Conference, the National Association of Corporate Directors, Thomson Financial and YCombinator. He has also regularly participated in the professional development programs of several regional and national law firms, covering topics including imbedded derivatives in M&A deal structures, earnouts and contingent payment structures, and fairness opinion best practices.

Mr. Benning has an MBA from the Harvard Graduate School of Business Administration, and a BA in Public Policy Analysis from the University of Pennsylvania, where he was Captain of the Heavyweight Crew. He is a Series 24 Registered Securities Principal with BML Securities LLC.

Mark A. King

Senior Partner

Back Bay Life Science Advisors

Mr. King is Co-founder and Senior Partner at Back Bay Life Science Advisors. In addition, he advises clients on corporate and therapeutic area growth strategies as well as commercial strategy and valuation for development-stage assets. Mr. King’s expertise spans the pharma, biotech, medical device and diagnostics industries in the U.S., Europe and Japan. .Prior to founding Back Bay, Mr. King was President and Founder of Back Bay Strategies and Kendall Strategies. Both Back Bay and Kendall were international life science consulting practices specializing in product development and commercial strategy, life cycle management and branding. Mr. King and his partners sold Kendall Strategies to WPP Group plc in 1999.Previously, Mr. King headed the commercial side of MGI Pharma, where he served as Vice President, Business Operations, a corporate officer of this NASDAQ listed company. At MGI, Mr. King acquired the company’s initial product portfolio, built an oncology sales and marketing organization and closed numerous R&D partnerships and product acquisition/licensing transactions as he headed the Company’s business development team.

At Bain & Company, Mr. King managed project teams working on business unit strategy, acquisitions and divestitures, cost reduction, and competitive strategy for clients in the information services, textile, steel and chemical industries.

At Baxter International, Mr. King helped reposition its plasma derivatives business and launch its total parenteral nutrition product line in Europe.

Mr. King holds an MBA with distinction from the Harvard Business School and an AB with honors in Economics and Chemistry from the University of North Carolina.

Reiner Christensen

President

Chameleon Pharma Consulting

Mr. Reiner Christensen looks back on more than 20 years of substantial international experience in Rx, Medical Device, Clinic, OTC and Food Supplements products in General Management.

He has previously worked for Ferrosan A/B (Copenhagen), Omega Pharma Group (Brussels) and Merck KGaA (Asia, Latin America, Europe & CEE/CIS), Hoechst AG (Frankfurt) and Richard Bitter AG (Vienna).

He has lived and worked in Asia, Latin America and different European countries.

His today focus in the Chameleon Pharma Consulting Group is on international Strategy, Marketing, Business Development, Regulatory and M&A.

Reiner holds a Diploma in Industrial Engineering & Management (Dipl. Wirtschaftsingenieur) and an Executive MBA from Ashridge.

Olaf Koenig

VP Business Development and New Product Planning Europe

Daiichi Sankyo Europe

Dr. Koenig started his career in the healthcare industry in 1997 at Molecular Simulations in Cambridge, United Kingdom as Product Manager for Molecular Modeling and Simulation solutions for the pharmaceutical industry.

He joined Merck KGaA in Darmstadt, Germany, in 1999, as Senior Manager in Business Development responsible for Business Intelligence and local European Licensing activities.

In 2002 Dr. Koenig joined former Sankyo European Headquarters in Munich, Germany, and established Daiichi Sankyo’s Licensing and Business Development Department in Europe. In this position he played a leading role in several licensing-in and acquisition projects, both for Europe and globally, including the acquisition of the oncology biotech company U3 Pharma in 2008. He is also member of Daiichi Sankyo’s global Senior Licensing Committee and Daiichi Sankyo’s European Management Team.

In 2009 he was promoted to Vice President Business Development & New Product Planning. In this dual role he is responsible for providing commercial guidance and input to Daiichi Sankyo’s in-house pipeline and for business development in Europe.

Dr. Koenig received his Ph.D. in Chemistry from the University of Berne, Switzerland

Huaizheng Peng

General Manager, International Operations

China Medical System Holdings

Former global investor and investment banker specialising in life science, biocenology and pharmaceuticals, Dr Huaizheng Peng is a General Manager of China Medical System Holdings, a publicly traded (HK: 0867) specialty pharmaceutical company with a market cap of multi-billion USD.  He is in charge of international operations for the firm, including pharmaceutical asset acquisition/ product licencing-in/out, international business development, outbound investment and asset management among others.

Prior to his pharmaceutical and financial industry career, he practiced medicine as a clinical lecturer in UCL Medical School, UK, after he received his Bachelor’s and Master’s degrees in Medicine from Hunan Medical College, PR China and his Doctoral of Philosophy in University of London, UK.

Barbara Krebs-Pohl

Senior Vice President, Head of Business Development

MorphoSys

Barbara is heading the business development team, including competitive intelligence, compound search & evaluation, and portfolio management, of MorphoSys AG, reporting to the CEO and co-founder of the company. Since she took over that role more than 10 years ago, she and her team have negotiated a multitude of deals, with more than 20 of the leading pharma and biotech companies worldwide, securing more than 400 million Euro in committed revenue for the company plus hundreds of millions of upside in milestones and royalties. Previously, she held various positions in research & development, project & alliance management and legal affairs within MorphoSys since 1998.

She received her Master degree in chemistry from University of Cologne, performed her master thesis at University hospital in Aachen, and holds a PhD in biochemistry from Mainz University with her PhD thesis performed in cooperation with Sir Greg Winter at the MRC in Cambridge, UK.

Juergen Langhaerig

former VP Business Development

Bavarian Nordic

Jürgen Langhärig is the former Vice President of Business Development at Bavarian Nordic  based at headquarters in Kvistgaard/Denmark. Jürgen joined Bavarian Nordic in 2008. Prior to this, Jürgen has 26 years’ experience in business development, strategy development and marketing, working with Zealand Pharma, Novo Nordisk,  Nycomed (now part of Takeda) and Sandoz (now Novartis).

Jürgen is the President of the Nordic Pharma Licensing Group and Vice President of the European Pharma Licening Group. He holds a Ph.D. in industrial microbiology, graduating from the University of Tübingen, Germany and having performed part of his Ph.D. at the Swiss Federal Institute of Technology in Zurich, Switzerland. Jürgen Langhärig holds an Executive MBA from the University of St. Gallen, Switzerland.